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There is a high risk of Plasmodium vivax parasitaemia following treatment of falciparum
malaria. Our study aimed to quantify this risk and the associated determinants using an
individual patient data meta-analysis in order to identify populations in which a policy of uni-
versal radical cure, combining artemisinin-based combination therapy (ACT) with a hypno-
zoitocidal antimalarial drug, would be beneficial.
Methods and findings
A systematic review of Medline, Embase, Web of Science, and the Cochrane Database of
Systematic Reviews identified efficacy studies of uncomplicated falciparum malaria treated
with ACT that were undertaken in regions coendemic for P. vivax between 1 January 1960
and 5 January 2018. Data from eligible studies were pooled using standardised methodol-
ogy. The risk of P. vivax parasitaemia at days 42 and 63 and associated risk factors were
investigated by multivariable Cox regression analyses. Study quality was assessed using a
tool developed by the Joanna Briggs Institute. The study was registered in the International
Prospective Register of Systematic Reviews (PROSPERO: CRD42018097400). In total, 42
studies enrolling 15,341 patients were included in the analysis, including 30 randomised
controlled trials and 12 cohort studies. Overall, 14,146 (92.2%) patients had P. falciparum
monoinfection and 1,195 (7.8%) mixed infection with P. falciparum and P. vivax. The median
age was 17.0 years (interquartile range [IQR] = 9.0–29.0 years; range = 0–80 years), with
1,584 (10.3%) patients younger than 5 years. 2,711 (17.7%) patients were treated with arte-
mether-lumefantrine (AL, 13 studies), 651 (4.2%) with artesunate-amodiaquine (AA, 6 stud-
ies), 7,340 (47.8%) with artesunate-mefloquine (AM, 25 studies), and 4,639 (30.2%) with
dihydroartemisinin-piperaquine (DP, 16 studies). 14,537 patients (94.8%) were enrolled
from the Asia-Pacific region, 684 (4.5%) from the Americas, and 120 (0.8%) from Africa. At
day 42, the cumulative risk of vivax parasitaemia following treatment of P. falciparum was
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31.1% (95% CI 28.9–33.4) after AL, 14.1% (95% CI 10.8–18.3) after AA, 7.4% (95% CI 6.7–
8.1) after AM, and 4.5% (95% CI 3.9–5.3) after DP. By day 63, the risks had risen to 39.9%
(95% CI 36.6–43.3), 42.4% (95% CI 34.7–51.2), 22.8% (95% CI 21.2–24.4), and 12.8%
(95% CI 11.4–14.5), respectively. In multivariable analyses, the highest rate of P. vivax
parasitaemia over 42 days of follow-up was in patients residing in areas of short relapse
periodicity (adjusted hazard ratio [AHR] = 6.2, 95% CI 2.0–19.5; p = 0.002); patients treated
with AL (AHR = 6.2, 95% CI 4.6–8.5; p < 0.001), AA (AHR = 2.3, 95% CI 1.4–3.7; p = 0.001),
or AM (AHR = 1.4, 95% CI 1.0–1.9; p = 0.028) compared with DP; and patients who did not
clear their initial parasitaemia within 2 days (AHR = 1.8, 95% CI 1.4–2.3; p < 0.001). The
analysis was limited by heterogeneity between study populations and lack of data from very
low transmission settings. Study quality was high.
Conclusions
In this meta-analysis, we found a high risk of P. vivax parasitaemia after treatment of P. fal-
ciparum malaria that varied significantly between studies. These P. vivax infections are
likely attributable to relapses that could be prevented with radical cure including a hypnozoi-
tocidal agent; however, the benefits of such a novel strategy will vary considerably between
geographical areas.
Author summary
Why was this study done?
• Plasmodium vivax is the most geographically widespread human malaria species; out-
side of sub-Saharan Africa, it almost invariably coexists with P. falciparum.
• A recent systematic review of 153 studies across 21 countries revealed that within 63
days of being treated for P. falciparum monoinfection, more than 15% of patients
treated with an artemisinin-based combination therapy (ACT) had an episode of P.
vivax malaria, far greater than expected for patients in similar locations who do not
have acute malaria.
• We hypothesised that patients presenting with P. falciparum in coendemic locations are
at high risk of carrying P. vivax dormant liver stages (hypnozoites) and would therefore
potentially benefit from presumptive radical cure.
What did the researchers do and find?
• We undertook an individual patient data meta-analysis to define the risk of vivax parasi-
taemia (blood stream infection) after treatment of P. falciparum malaria in different
coendemic environments and to explore the factors underlying these risks.
• In total, 42 studies enrolling 15,341 patients were included in the analysis. By day 63, the
risk of P. vivax ranged from 12.8% following dihydroartemisinin-piperaquine (DP) to
42.4% following artesunate-amodiaquine (AA).
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• The highest rate of P. vivax malaria was in patients residing in areas with high risk of
relapses and those who were slow to clear their initial parasitaemia.
What do these findings mean?
• There is a high risk of vivax malaria after treatment of falciparum infection after all
ACTs, although the risk varies substantially between locations.
• The correlation between the risk of P. vivax and the initial clearance of P. falciparum
raises the possibility that the host response to acute malaria may be triggering the reacti-
vation of P. vivax dormant liver stages.
• Universal radical cure with treatment to kill the liver stages may be warranted for reduc-
ing P. vivax, but the benefits will vary considerably between geographical locations, and
further prospective clinical efficacy studies will be needed to determine the risks and
benefits of such a strategy.
Introduction
Malaria continues to exert a huge global health burden, with the latest estimates suggesting
there are more than 228 million cases per year, associated with 405,000 deaths [1]. In 2015, the
World Health Assembly set a target to reduce malaria prevalence by 90% by 2030 [2].
Although the burden of malaria has fallen in many regions, global estimates of malaria cases
have plateaued and even risen in some areas over the past 5 years [1]. There has also been a rel-
ative rise in the proportion of malaria due to Plasmodium vivax outside of sub-Saharan Africa
[3]. P. vivax is more difficult to eliminate than P. falciparum because it can form dormant liver
stages (hypnozoites) that can reactivate weeks to months after the initial infection. Treatment
of both the blood and liver stages is referred to as radical cure. If the proposed ambitious
malaria elimination targets are to be achieved, innovative strategies are needed to provide safe
and effective radical cure to the high proportion of individuals harbouring occult as well as cir-
culating P. vivax parasites [4].
Where P. vivax and P. falciparum are coendemic (Asia, the Horn of Africa, and the Ameri-
cas), reports have documented a high risk of P. vivax parasitaemia following treatment of P.
falciparum infection [5, 6]. A recent meta-analysis of P. falciparum clinical trials revealed that
within 63 days, 24% of patients presenting with P. falciparum had a recurrence with P. vivax,
and almost 70% of all parasitological recurrences were due to P. vivax [7]. The high risk of P.
vivax has been hypothesised to be due to reactivation of the dormant liver stages of parasites,
although the mechanisms underlying this are not well understood. In areas where the risk of P.
vivax parasitaemia is high, broadening the indication for hypnozoitocidal treatment to include
patients presenting with uncomplicated malaria due to either P. vivax or P. falciparum (univer-
sal radical cure) has potential to reduce the subsequent risk of vivax parasitaemia and its ongo-
ing transmission [8].
Radical cure with 8-aminoquinoline compounds can reduce the risk of P. vivax relapse sig-
nificantly; however, both primaquine and tafenoquine can cause haemolysis in individuals
with glucose-6-phosphate dehydrogenase (G6PD) deficiency [9]. Thus, the risk versus benefit
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of a policy of universal radical cure will depend upon quantifying the inherent risk of P. vivax
recurrence and associated cofactors in different endemic settings, an approach that is more
amenable to an individual patient data meta-analysis than our previous study-level systematic
review [7].
The aim of this individual patient data meta-analysis was to define the risk of vivax parasi-
taemia after falciparum infection in different coendemic environments and to explore the fac-
tors underlying these risks in order to identify populations in which a policy of universal
radical cure, with blood schizontocidal treatment plus either primaquine or tafenoquine,
would be most beneficial.
Methods
Search strategy and selection criteria
A previous systematic review was used to identify suitable studies [7]. In brief, Medline,
Embase, Web of Science, and the Cochrane Database of Systematic Reviews were searched for
prospective studies published between 1 January 1960 and 5 January 2018 in any language that
included supervised treatment of patients with uncomplicated P. falciparum infection (includ-
ing monoinfection and mixed P. falciparum and P. vivax infection) located in areas coendemic
for P. falciparum and P. vivax (S1 Box). Countries were considered coendemic if indigenous P.
falciparum and P. vivax cases were reported or suspected in 2016 [10].
In the original systematic review, studies were included if they explicitly reported the pres-
ence or absence of recurrent parasitaemia. Studies were excluded if patients were followed less
than 28 days, if patients were only followed passively, or if the full text manuscript was unavail-
able. Because primaquine and tafenoquine are contraindicated in pregnant women and not a
clinical priority in patients presenting with severe malaria, studies only enrolling these patients
were also excluded from the analysis. Identification of studies and extraction of data were
undertaken by 2 independent authors, with discrepancies resolved by discussion with a third
author.
To improve the generalisability of the results, the inclusion criteria for this individual
patient data meta-analysis were restricted further to include only studies in which patients
were treated with 1 of 4 widely used ACTs: artemether-lumefantrine (AL), artesunate-amodia-
quine (AA), artesunate-mefloquine (AM), or dihydroartemisinin-piperaquine (DP). Further-
more, because it was not always apparent whether recurrent P. vivax was systematically
documented during follow-up, studies were only included if at least 1 episode of P. vivax para-
sitaemia during follow-up was reported in the manuscript. Additional study-level exclusions
were if studies only included travellers or soldiers or only patients with hyperparasitaemic
infection, because these either reflected malaria acquired from diverse locations or a biased
population of patients attending a clinic in a malaria-endemic setting. Investigators of eligible
studies were invited to participate in this analysis and share their study’s individual patient
data with the WorldWide Antimalarial Resistance Network (WWARN) repository. Shared
data were anonymised and standardised using the WWARN Data Management and Statistical
Analysis Plans [11].
In addition to the systematic review, the pre-existing WWARN repository was searched for
studies of uncomplicated P. falciparum monoinfection or mixed infection in which at least 1
patient was recorded as having P. vivax parasitaemia during study follow-up. This was under-
taken to identify unpublished studies and published studies that did not report P. vivax parasi-
taemia during follow-up in the manuscript. Patient data from eligible studies were collated
together with those from the systematic review for analysis.
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Data collection and definitions
Demographic and clinical data including age, sex, weight, baseline species and parasite density,
presence and species of parasites at follow-up, baseline gametocytaemia, baseline body temper-
ature, and haemoglobin (Hb) or haematocrit at baseline and follow-up were included in the
data set. Patient-level data were excluded if baseline parasitaemia was not available or did not
include P. falciparum species, patients were treated with adjunctive antimalarials, or there was
an enrolment violation according to supplied study data.
Haematocrit was converted to Hb using the formula Hb = (Haematocrit − 5.62)/2.6 [12].
The maximum value was used when multiple Hb measurements were recorded on a single
day. The nadir Hb following acute P. falciparum malaria occurs between day 3 and 7, with
most studies measuring the first follow-up Hb 7 days after starting antimalarial treatment [13].
The early decline and recovery of Hb was therefore assessed from the Hb measured between
days 6 and 8 inclusive. Anaemia was defined as a Hb concentration less than 10 g/dL. A high
parasite count was defined as a parasite count greater than 100,000 parasites per μL. Based on
geographical location, studies were categorised into long or short P. vivax relapse periodicity
using data from the Malaria Atlas Project (MAP) [14]. A median time to relapse of�47 days
was categorised as short relapse periodicity. Subnational malaria parasite incidence was esti-
mated from MAP models [15].
Data regarding the supervision of drug administration were extracted from publications or
study protocols. Drug administration was categorised as ‘supervised’ if the entire treatment
regimen was supervised, ‘partially supervised’ if only some treatment doses were supervised,
and ‘not specified if data were not available. The year of enrolment was defined in the first
instance from individual patient data or, if unavailable, from the median year during which
patients were enrolled into the study or as 2 years prior to the year of publication. The study
was registered in the International Prospective Register of Systematic Reviews (PROSPERO:
CRD42018097400), and the protocol is available at www.wwarn.org/working-together/study-
groups/vivax-after-falciparum-study-group (S1 PRISMA Checklist).
Outcomes
The primary outcome was the risk of P. vivax parasitaemia (P. vivax monoinfection or mixed
infection) between days 7 and 42. Secondary outcomes were the risk of P. vivax parasitaemia
between days 7 and 28 and days 7 and 63.
Statistical analysis
Statistical analyses were undertaken using Stata software, version 15.1 (Stata Corporation, Col-
lege Station, TX, USA) and R version 3.5.1 (R Foundation for Statistical Computing, Vienna,
Austria), according to an a priori statistical analysis plan [16]. The cumulative risk of periph-
eral parasitaemia was calculated using Kaplan–Meier survival analyses. Patients were right-
censored at their first recurrence, day of last follow-up, the day prior to a blood smear result
gap>18 days, or the day of the planned outcome assessment [11]. Following peer review, pre-
diction intervals were calculated for the cumulative risk of P. vivax parasitaemia [17].
To estimate the association between ACTs with the rate of P. vivax parasitaemia, Cox’s pro-
portional hazards regression was used with shared frailty for study sites and adjustment for
age, sex, baseline parasitaemia, regional relapse periodicity, P. falciparum gametocytes, mixed
infection at baseline, and Hb. The proportional hazards assumption was assessed visually
using plots of observed versus expected values. Body weight and geographical location were
not included because of collinearity with age and relapse periodicity, respectively. To investi-
gate the association between the change in Hb and the rate of P. vivax parasitaemia, the
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absolute fall in Hb between day 0 and day 7 was included in the multivariable Cox regression
model.
The association between day of first parasite clearance (defined as parasite count below the
microscopic limit of detection) and risk of P. vivax parasitaemia between days 7 and 63 was
assessed by Cox’s proportional hazards regression with shared frailty for study sites and adjust-
ment for age, sex, baseline parasitaemia, regional relapse periodicity, P. falciparum gameto-
cytes, mixed infection at baseline, Hb at baseline, and treatment. Patients treated with single
low-dose primaquine were excluded. A subgroup analysis restricted data to patients treated
with AL with a minimum of 42 days of follow-up to reduce the impact of slowly eliminated
partner drugs with prolonged post-treatment prophylactic effect on outcome assessment. This
subgroup was used to explore the association between the background incidence of P. falcipa-
rum and P. vivax and the risk of P. vivax parasitaemia. Following peer review, additional sub-
group analyses were included for the other ACTs.
Bias related to individual studies was assessed using a tool developed by the Joanna Briggs
Institute (S1 Text) [18] and in a sensitivity analysis, with removal of 1 study at a time and cal-
culation of the coefficient of variation. Included and targeted studies that were not included
were compared using baseline characteristics.
Ethics
All data included in this analysis were obtained in accordance with ethical approvals from the
country of origin. The data are fully anonymised and cannot be traced back to identifiable
individuals. This systematic review did not require separate ethical approval according to the
guidelines of the Oxford Central University Research Ethics Committee.
Results
There were 153 clinical trials enrolling P. falciparum patients published between 1 January
1960 and 5 January 2018 and identified as part of the previous systematic review [7]. Of these,
51 (33.3%) studies enrolling 15,903 patients between 1991 and 2016 included treatment with
the 4 major ACTs and were eligible for inclusion in this analysis. Individual patient data were
available for 9,410 (59.2%) patients from 26 studies [19–44] (S1 Table and S2 Table). An addi-
tional 32 published and 2 unpublished studies with individual patient data in the WWARN
repository were screened for inclusion, of which 16 studies were identified as also being eligible
for the analysis [45–58]. In total, 42 studies enrolling 15,341 eligible patients were included in
the analysis (Fig 1, S2 Table and S3 Table).
Of the studies included, 2,711 (17.7%) patients were treated with AL (13 studies), 651
(4.2%) with AA (6 studies), 7,340 (47.8%) with AM (25 studies), and 4,639 (30.2%) with DP
(16 studies) (Fig 1 and S2 Table). In 2 studies, 448 patients were coadministered a single dose
of primaquine. Patients were followed for 28 days in 3 studies (n = 670 patients), 42 days in 25
studies (n = 6,510 patients), 56 days in 1 study (n = 2,072 patients), 63 days in 11 studies
(n = 5,653 patients), and a mixture of 28 and 63 days in 2 studies (436 patients).
The patients’ baseline characteristics are presented in Table 1. Overall, 14,146 (92.2%)
patients had P. falciparum monoinfection and 1,195 (7.8%) mixed infection with P. falciparum
and P. vivax confirmed by blood film microscopy. The median age was 17.0 years (interquar-
tile range [IQR] = 9.0–29.0 years; range = 0–80 years), with 1,584 (10.3%) patients younger
than 5 years. Most patients (14,258; 92.9%) were recruited in areas with short relapse periodic-
ity, and 82.5% (12,652) were enrolled in the Greater Mekong Subregion (S1 Fig). All 684
(4.5%) patients enrolled in the Americas were treated with AM or DP, whereas in Africa, all
patients (120; 0.8%) were treated with AL. The 14,537 (94.8%) patients enrolled in Asia were
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treated with 1 of the 4 main ACTs (Table 1). The median parasite density at baseline was
7,544/μL (IQR = 2,000–28,021; range = 7–479,280). Baseline Hb data were available for 12,184
(79.4%) patients, of whom 27.6% (3,358) were anaemic (Hb <10 g/dL). No issues impacting
data integrity were identified during collation of individual patient data. Studies that were tar-
geted but for which data were not available were more likely to have been conducted in Africa;
these studies had a similar median age and sex distribution to those included (S4 Table and S5
Table). Study quality was generally high (S1 Text).
The overall risk of P. vivax parasitaemia
Recurrent parasitaemia between day 7 and 42 was recorded in 2,020 (13.2%) patients, of
whom 1,047 (51.8%) had P. vivax monoinfection, 99 (4.9%) mixed P. vivax and P. falciparum
infection, and 874 (43.3%) P. falciparum monoinfection. The overall cumulative risks of recur-
rent parasitaemia of any species were 8.1% (95% CI 7.7–8.6) by day 28, 16.8% (16.2–17.5) by
day 42, and 30.5% (29.4–31.6) by day 63. The corresponding cumulative risks of P. vivax para-
sitaemia (monoinfection or mixed infection) were 3.7% (3.4–4.1), 10.2% (9.6–10.7), and 22.2%
Fig 1. Study flowchart. AA, artesunate-amodiaquine; ACT, artemisinin-based combination therapy; AL, artemether-lumefantrine; AM, artesunate-
mefloquine; DP, dihydroartemisinin-piperaquine; WWARN, WorldWide Antimalarial Resistance Network.
https://doi.org/10.1371/journal.pmed.1003393.g001
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Table 1. Demographics and baseline characteristics.
AL, n (%) (n = 2,711) AA, n (%) (n = 651) AM, n (%) (n = 7,340) DP, n (%) (n = 4,639) Overall, n (%) (n = 15,341)
Sex�
Female 958 (35.4%) 252 (38.8%) 3,015 (41.1%) 1,391 (30.2%) 5,616 (36.7%)
Male 1,752 (64.6%) 398 (61.2%) 4,323 (58.9%) 3,214 (69.8%) 9,687 (63.3%)
Age, years†
Median (IQR) 18.0 (9.0–28.0) 16.0 (8.0–28.0) 14.0 (8.0–25.0) 22.0 (12.0–32.0) 17.0 (9.0–29.0)
�15 1,596 (58.9%) 352 (54.2%) 3,535 (48.2%) 3,275 (70.8%) 8,758 (57.1%)
5 to <15 753 (27.8%) 252 (38.8%) 2,994 (40.8%) 984 (21.3%) 4,983 (32.5%)
<5 361 (13.3%) 45 (6.9%) 810 (11.0%) 368 (8.0%) 1,584 (10.3%)
Weight, kg‡
Median (IQR) 44.0 (21.0–52.0) 38.0 (20.5–49.4) 35.9 (18.3–49.0) 42.5 (19.0–53.0) 39.0 (19.0–50.0)
5 to <15 350 (13.3%) 67 (10.3%) 1,008 (14.6%) 443 (16.6%) 1,868 (14.5%)
15 to <25 418 (15.8%) 134 (20.7%) 1,575 (22.8%) 444 (16.7%) 2,571 (20.0%)
25 to <35 237 (9.0%) 80 (12.3%) 783 (11.3%) 210 (7.9%) 1,310 (10.2%)
35 to <45 361 (13.7%) 126 (19.4%) 1,004 (14.5%) 309 (11.6%) 1,800 (14.0%)
45 to <55 833 (31.6%) 155 (23.9%) 1,693 (24.5%) 677 (25.4%) 3,358 (26.1%)
55 to <80 438 (16.6%) 86 (13.3%) 837 (12.1%) 569 (21.4%) 1,930 (15.0%)
�80 2 (0.1%) 0 (0.0%) 9 (0.1%) 12 (0.5%) 23 (0.2%)
Relapse periodicity
Long 120 (4.4%) 202 (31.0%) 499 (6.8%) 262 (5.6%) 1,083 (7.1%)
Short 2,591 (95.6%) 449 (69.0%) 6,841 (93.2%) 4,377 (94.4%) 14,258 (92.9%)
Geographical region
Asia-Pacific 2,591 (95.6%) 651 (100.0%) 6,918 (94.3%) 4,377 (94.4%) 14,537 (94.8%)
The Americas 0 (0.0%) 0 (0.0%) 422 (5.7%) 262 (5.6%) 684 (4.5%)
Africa 120 (4.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 120 (0.8%)
Treatment supervision
Not specified 67 (2.5%) 202 (31.0%) 397 (5.4%) 0 (0.0%) 666 (4.3%)
Supervised 1,843 (68.0%) 294 (45.2%) 5,987 (81.6%) 2,182 (47.0%) 10,306 (67.2%)
Partial supervised 801 (29.5%) 155 (23.8%) 956 (13.0%) 2,457 (53.0%) 4,369 (28.5%)
P. falciparum gametocytes present§ 238/1,959 (12.1%) 93/428 (21.7%) 697/5,765 (12.1%) 495/3,568 (13.9%) 1,523/11,720 (13.0%)
Mixed infection 183/2,711 (6.8%) 42/651 (6.5%) 712/7,340 (9.7%) 258/4,639 (5.6%) 1,195/15,341 (7.8%)
Baseline parasitaemia¶
Median (IQR) 9,120 (1,900–39,600) 8,680 (2,364–24,507) 7,213 (1,976–25,622) 7,574 (2,048–25,120) 7,544 (2,000–28,022)
�100,000 parasites per μL 2,507 (92.5%) 638 (98.0%) 6,610 (94.2%) 4,290 (94.5%) 14,045 (94.2%)
>100,000 parasites per μL 204 (7.5%) 13 (2.0%) 404 (5.8%) 250 (5.5%) 871 (5.8%)
Hb, g/dL; mean (SD)|| 10.4 (2.7) 10.7 (2.4) 10.8 (2.5) 10.9 (2.7) 10.8 (2.6)
Anaemic, Hb < 10 g/dL 721/2,586 (27.9%) 212/530 (40.0%) 1,655/6,481 (25.5%) 770/2,587 (29.8%) 3,358/12,184 (27.6%)
Fever, temperature >37.5˚C�� 1,331/2,547 (52.3%) 332/440 (75.5%) 3,713/6,565 (56.6%) 1,099/2,221 (49.5%) 6,475/11,773 (55.0%)
�Data not available for 38 patients.
†Data not available for 16 patients.
‡Data not available for 2,481 patients.
§Data not available for 3,623 patients.
¶Parasite count data not available for 427 patients.
||Data not available for 3,159 patients.
��Data not available for 3,570 patients.
Abbreviations: AA, artesunate-amodiaquine; AL, artemether-lumefantrine; AM, artesunate-mefloquine; DP, dihydroartemisinin-piperaquine; Hb, haemoglobin; IQR,
interquartile range; n, number; SD, standard deviation.
https://doi.org/10.1371/journal.pmed.1003393.t001
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(21.1–23.3), respectively, and for P. falciparum parasitaemia (monoinfection) were 4.5% (4.2–
4.9), 7.3% (6.9–7.8), and 10.4% (9.8–11.2), respectively.
At day 42, the cumulative risk of P. vivax parasitaemia was 31.1% (95% CI 28.9–33.4; pre-
diction interval) after AL, 14.1% (10.8–18.3) after AA, 7.4% (6.7–8.1) after AM, and 4.5% (3.9–
5.3) after DP. By day 63, the risk of P. vivax parasitaemia had risen to 39.9% (36.6–43.3) after
AL, 42.4% (34.7–51.2) after AA, 22.8% (21.2–24.4) after AM, and 12.8% (11.4–14.5) after DP
(Fig 2). There was substantial heterogeneity in risk between studies (Fig 3, Fig 4, Fig 5, Fig 6
and S6 Table). Of the 39 studies in which patients were followed for at least 42 days, the risk of
P. vivax parasitaemia was�20% in 75.0% (9/12) of studies following AL, 20.0% (1/5) following
AA, 21.7% (5/23) following AM, and 25.0% (4/16) following DP.
Risk factors for P. vivax parasitaemia
The rate of P. vivax parasitaemia was greatest in children. Compared with adults, children
under 5 years had a hazard ratio (HR) = 4.40, 95% CI 3.66–5.29; p< 0.001, and children 5 to
<15 years had an HR = 2.19, 1.90–2.53; p< 0.001. Other significant univariable baseline risk
factors for P. vivax parasitaemia were high parasite count (>100,000 parasites per μL)
(HR = 1.54, 1.24–1.90; p< 0.001), mixed P. falciparum and P. vivax infection (HR = 2.54,
Fig 2. Cumulative risk (Kaplan–Meier analysis) of P. vivax parasitaemia following ACTs. �ACTs (AA, AL, AM,
DP). †P. vivax recurrence includes recurrences with P. vivax monoinfection or mixed-species infection. AA,
artesunate-amodiaquine; ACT, artemisinin-based combination therapy; AL, artemether-lumefantrine; AM,
artesunate-mefloquine; DP, dihydroartemisinin-piperaquine.
https://doi.org/10.1371/journal.pmed.1003393.g002
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Fig 3. Cumulative risk (Kaplan–Meier analysis) of P. vivax parasitaemia after P. falciparum infection by study for AL. AL,
artemether-lumefantrine.
https://doi.org/10.1371/journal.pmed.1003393.g003
Fig 4. Cumulative risk (Kaplan–Meier analysis) of P. vivax parasitaemia after P. falciparum infection by study for AA. AA,
artesunate-amodiaquine.
https://doi.org/10.1371/journal.pmed.1003393.g004
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2.14–3.01; p < 0.001), and P. falciparum gametocytaemia (HR = 1.57, 1.24–1.99; p< 0.001).
Increasing baseline Hb was a protective factor (HR = 0.88 per 1 g/dL increase, 0.86–0.90;
p< 0.001). Patients enrolled into studies conducted in regions of short relapse periodicity had
a significantly greater rate of P. vivax parasitaemia than those enrolled into studies conducted
in regions of long relapse periodicity (HR = 8.61, 2.34–31.65; p = 0.001) (Table 2).
In multivariable analysis, younger afge (adjusted HR [AHR] = 3.04, 95% CI 2.39–3.87,
p< 0.001 and AHR = 1.81, 95% CI 1.52–2.15, p< 0.001 comparing age<5 years and age 5 to
<15 years to adults, respectively), short relapse periodicity (AHR = 6.20, 95% CI 1.98–19.47;
p = 0.002), P. falciparum gametocytaemia (AHR = 1.40, 1.10–1.79; p = 0.007), mixed infection
(AHR = 2.20, 1.79–2.70; p< 0.001), high parasite count (AHR = 1.59, 1.22–2.08; p = 0.001),
male sex (AHR = 1.26, 95% CI 1.08–1.46; p = 0.003), and low baseline Hb (AHR = 0.94 per 1
g/dL increase, 0.90–0.97; p< 0.001) were independent risk factors for P. vivax parasitaemia
(Table 2). Compared with patients treated with DP, the rate of P. vivax parasitaemia was
Fig 5. Cumulative risk (Kaplan–Meier analysis) of P. vivax parasitaemia after P. falciparum infection by study for
AM. AM, artesunate-mefloquine.
https://doi.org/10.1371/journal.pmed.1003393.g005
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greater after AL (AHR = 6.23, 4.55–8.53; p< 0.001), AA (AHR = 2.26, 1.40–3.65; p = 0.001),
and AM (AHR = 1.40, 1.04–1.89; p = 0.028) (Fig 7). Removal of 1 study at a time did not reveal
bias related to any individual study (S7 Table).
The mean Hb concentration at baseline was 11.8 g/dL (standard deviation [SD] 2.35) com-
pared with 10.9 g/dL (SD 2.03) on day 7 in 6,328 patients with available data. The overall mean
fall in Hb between baseline and day 7 was 0.87 g/dL (SD 1.71, range −8.8 to 11.6). The rate of
P. vivax parasitaemia did not correlate with the absolute fall in Hb in univariable or multivari-
able analysis.
Association between risk of P. vivax parasitaemia and parasite clearance of
initial P. falciparum infection
Overall, 46.3% (4,260/9,208) of patients were aparasitaemic by day 1 and 89.9% (8,277/9,208)
by day 2; S8 Table. The risk of P. vivax parasitaemia between days 7 and 63 was 16.3% (95%
CI: 14.7–18.1) in the patients clearing their parasitaemia on day 1, 22.6% (95% CI: 20.7–24.5)
in patients clearing on day 2, and 29.2% (95% CI: 25.1–33.7) in patients clearing after this. The
rate of P. vivax parasitaemia by day 63 was investigated in a multivariable model controlling
for confounding factors. Compared with patients clearing their peripheral P. falciparum para-
sites by day 1, the rate of P. vivax was significantly greater in those clearing their initial parasi-
taemia on day 2 (AHR = 1.48, 95% CI 1.27–1.73; p< 0.001) and even greater in those clearing
their parasitaemia thereafter (AHR = 1.82, 1.44–2.30; p< 0.001) (Fig 8 and S9 Table). Removal
of 1 study at a time did not reveal bias related to any individual study (S10 Table).
Fig 6. Cumulative risk (Kaplan–Meier analysis) of P. vivax parasitaemia after P. falciparum infection by study for
DP. DP, dihydroartemisinin-piperaquine.
https://doi.org/10.1371/journal.pmed.1003393.g006
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Table 2. Risk factors for P. vivax parasitaemia after falciparum infection between days 7 and 42 in patients with different ACTs.
Total
Patients
Patients with P. vivax
Parasitaemia
Risk of P. vivax Parasitaemia at
Day 42
Univariable Analyses Multivariable Analyses�
Crude HR (95%
CI)




Male 9,687 714 10.32 (9.62–11.06) 1.10 (0.97–1.24) 0.125 1.26 (1.08–1.46) 0.003
Female 5,616 426 9.94 (9.08–10.88) Reference Reference
Age, per year increase 15,325 1,140 0.95 (0.95–0.96) <0.001 –
Age category, years
<5 1,584 313 24.95 (22.63–27.45) 4.40 (3.66–5.29) <0.001 3.04 (2.39–3.87) <0.001
5 to <15 4,983 462 11.90 (10.92–12.96) 2.19 (1.90–2.53) <0.001 1.81 (1.52–2.15) <0.001
�15 8,758 365 6.01 (5.44–6.64) Reference Reference
Weight per kg
increase
12,860 1,116 0.97 (0.96–0.97) <0.001 –
Relapse periodicity
Short 14,258 1,125 10.85 (10.27–11.47) 8.61 (2.34–31.65) 0.001 6.20 (1.98–19.47) 0.002
Long 1,083 15 1.73 (1.05–2.87) Reference Reference
Geographical region
Africa 120 7 6.65 (3.23–13.46) 0.27 (0.03–2.65) 0.261 –
The Americas 684 7 1.11 (0.53–2.31) 0.08 (0.01–0.74) 0.026 –
Asia-Pacific 14,537 1,126 10.74 (10.16–11.35) Reference –
P. falciparum gametocytes
Yes 1,523 222 17.84 (15.81–20.09) 1.57 (1.24–1.99) <0.001 1.40 (1.10–1.79) 0.007
No 10,197 575 8.12 (7.50–8.79) Reference Reference
Mixed infection
Yes 1,195 184 21.82 (19.15–24.80) 2.54 (2.14–3.01) <0.001 2.20 (1.79–2.70) <0.001
No 14,146 956 9.21 (8.67–9.79) Reference Reference
Parasitaemia, parasites per μL
Every 10-times
increase
14,916 1,134 1.31 (1.20–1.41) <0.001 –
>100,000 parasites/
μL
871 112 17.68 (14.90–20.91) 1.54 (1.24–1.90) <0.001 1.59 (1.22–2.08) 0.001
�100,000 parasites/
μL
14,045 1,022 9.93 (9.36–10.52) Reference Reference
Hb every 1 g/dL
increase
12,184 1,090 0.88 (0.86–0.90) <0.001 0.94 (0.90–0.97) <0.001
Anaemic, Hb < 10 g/dL
Yes 3,358 482 18.55 (17.09–20.10) 1.70 (1.49–1.94) <0.001 –
No 8,826 608 8.94 (8.29–9.65) Reference –
Drug
AL 2,711 522 31.08 (28.89–33.40) 5.18 (4.10–6.56) <0.001 6.23 (4.55–8.53) <0.001
AA 651 47 14.07 (10.77–18.27) 1.75 (1.19–2.55) 0.004 2.26 (1.40–3.65) 0.001
AM 7,340 423 7.36 (6.71–8.06) 1.37 (1.09–1.72) 0.006 1.40 (1.04–1.89) 0.028
DP 4,639 148 4.50 (3.85–5.27) Reference Reference
�Geographical region and weight excluded from multivariable analysis due to collinearity with relapse periodicity and age.
Abbreviations: AA, artesunate-amodiaquine; ACT, artemisinin-based combination therapy; AL, artemether-lumefantrine; AM, artesunate-mefloquine; CI, confidence
interval; DP, dihydroartemisinin-piperaquine; Hb, haemoglobin; HR, hazard ratio.
https://doi.org/10.1371/journal.pmed.1003393.t002
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A sensitivity analysis including patients treated with single low-dose primaquine did not
change these results substantially (compared with patients who cleared parasitaemia by day 1,
AHR = 1.48 [95% CI 1.27–1.73] if cleared on day 2 and AHR = 1.82 [95% CI 1.44–2.29] if
cleared thereafter).
Site factors associated with risk of P. vivax parasitaemia following
treatment
The study-specific risks of P. vivax during follow-up are presented in Fig 3, Fig 4, Fig 5 and Fig
6. The risk of P. vivax parasitaemia at day 42 was greatest following treatment with AL. Twelve
studies across 18 study sites and 7 countries enrolled and treated 2,562 patients with AL who
were followed for 42 days or longer (S2 Fig). Nine (75%) studies enrolled children younger than
5 years. The study-specific risk of P. vivax at day 42 varied from 0% to 63.8%. The risk was
�20% in study sites from Thailand (4 study sites), Papua New Guinea (PNG) (4 study sites),
Myanmar (3 study sites), and Indonesia (1 study site); 12%–26% in 3 study sites from Bangla-
desh; 0%–7% in 2 study sites from Ethiopia; and 2.0% in 1 study from Laos (Fig 3). The corre-
sponding data for the other treatment arms are presented in Fig 4, Fig 5, Fig 6 and S11 Table.
Fig 7. Risk of P. vivax parasitaemia following falciparum infection between day 7 and day 42 according to treatment. Dotted lines demonstrate 95% CIs.
Figure adjusted for age, sex, baseline parasitaemia, regional relapse periodicity, P. falciparum gametocytes, mixed infection, and baseline Hb, assuming no study-site effect.
AA, artesunate-amodiaquine; AL, artemether-lumefantrine; AM, artesunate-mefloquine; DP, dihydroartemisinin-piperaquine; Hb, haemoglobin.
https://doi.org/10.1371/journal.pmed.1003393.g007
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Using subnational data, the estimated incidence of P. falciparum at each site varied from
0.5 to 154 cases per 1,000 person-years, and the background incidence of P. vivax varied from
1.6 to 151 cases per 1,000 person-years. The risk of P. vivax following AL was correlated with
the site-specific background incidence of P. vivax (rs = 0.676, p = 0.0029) and incidence of P.
falciparum (rs = 0.607, p = 0.0098) (Fig 9). However, after controlling for confounding factors
in a Cox regression model, neither of the background incidences were associated significantly
with the risk of P. vivax (AHR = 0.99, 0.97–1.02, p = 0.634 and AHR = 1.00, 0.99–1.02,
p = 0.629, respectively, for every 1 case increase per 1,000 person-years) (S12 Table). The
results were similar for the other ACTs (S13 Table, S14 Table, S15 Table, S3 Fig, S4 Fig, S5
Fig). The year of enrolment was not independently associated with the risk of P. vivax
(AHR = 0.93 per year later, 0.84–1.03; p = 0.173).
Fig 8. Risk of P. vivax parasitaemia following falciparum infection between days 7 and 63 according to treatment and day of parasite clearance: (A) AL, (B) AA, (C)
AM, and (D) DP. Figure adjusted for age, sex, baseline parasitaemia, regional relapse periodicity, P. falciparum gametocytes, mixed infection at baseline, and Hb at
baseline, assuming no study-site effect. AA, artesunate-amodiaquine; AL, artemether-lumefantrine; AM, artesunate-mefloquine; DP, dihydroartemisinin-piperaquine; Hb,
haemoglobin.
https://doi.org/10.1371/journal.pmed.1003393.g008
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Discussion
Our individual patient data meta-analysis, including more than 15,000 patients, confirms a
high risk of P. vivax parasitaemia following treatment of P. falciparum with ACTs; however,
there was marked heterogeneity between study populations and sites. The risk of P. vivax was
highest in studies undertaken in regions with short relapse periodicity and in patients who
were young or presented with mixed-species infections or a high baseline parasitaemia.
Overall, 10% of patients treated with an ACT had P. vivax recurrence by day 42, and this
increased to 22% by day 63. The risk of P. vivax was significantly lower in patients treated with
an ACT containing a slowly eliminated partner drug such as piperaquine, mefloquine, and
amodiaquine [5, 7]. Lumefantrine is eliminated faster, with a half-life of 4 days, and after 16
days (4 half-lives) provides minimal post-treatment prophylaxis against P. vivax relapses [59].
This is reflected by the high risk of P. vivax parasitaemia following AL, which reached 31% by
day 42.
The heterogeneity in the risk of P. vivax was highlighted in our recent systematic review of
clinical trials undertaken in coendemic areas [7] and has been investigated further in a review
of trials from the eastern border of Myanmar [60]. On the Thailand–Myanmar border, the risk
of P. vivax parasitaemia within 42 days of treatment of falciparum malaria exceeded 20%
between 2003 and 2010 and reached 85% in 1 study. However, after 2010, the risk fell to less
Fig 9. Risk of P. vivax parasitaemia at day 42 following treatment with AL according to background subnational
incidence of P. vivax (A) and P. falciparum (B). rs = 0.676, p = 0.0029 (A) and rs = 0.607, p = 0.0098 (B). AL,
artemether-lumefantrine.
https://doi.org/10.1371/journal.pmed.1003393.g009
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than 5%. The authors hypothesise that the decline in the risk of P. vivax was attributable to
substantial improvements in malaria control and thus a decline in the proportion of patients
presenting with P. falciparum who were coinfected with P. vivax. A key determinant of P.
vivax relapse is the number of hypnozoite parasites present in the liver, which varies with local
P. vivax transmission intensity, immunity, and sporozoite inoculum [61]. Although the risk of
P. vivax was correlated positively with the predicted background incidence of both P. vivax
and P. falciparum, this was not apparent after adjusting for confounding factors. We observed
no temporal trends indicative of a lower risk of P. vivax parasitaemia in more recent studies.
This may relate to the relatively few studies available to compare the use of an individual ACT
at a single site, lack of temporally distinct data from multiple studies in the same regions, or
heterogeneity between study populations from different locations. Incidence estimates are also
inexact, relying on subnational regional data that may not equate to the study site and do not
account for seasonal variation of transmission [15]. There is also a risk of inclusion bias, with
prospective clinical efficacy studies generally undertaken in regions with a relatively high
malaria burden to ensure adequate recruitment. The ability to compare the effect of malaria
prevalence between clinical efficacy studies is therefore likely to be limited compared with data
from longitudinal cohorts [62].
Our individual patient data meta-analysis confirms an increased risk of recurrence in
regions where the duration between P. vivax relapses is short [5, 7] and highlights the addi-
tional risks of young age, high baseline parasitaemia, low baseline Hb, and presenting with
either mixed-species infection or P. falciparum gametocytes. More than 15% of patients pre-
senting with mixed infection of P. falciparum and P. vivax had P. vivax parasitaemia within 42
days, supporting the World Health Organization (WHO) recommendation for the use of pri-
maquine radical cure in these patients. However, the high risk of P. vivax was also apparent in
those presenting with P. falciparum monoinfection. We could not determine whether recur-
rences were due to relapse or reinfection in patients continuing to reside in a malaria-endemic
area. The subnational incidence estimates of P. vivax infection in the study sites included in
our study ranged from 0.2 to 151 per 1,000 person-years [15]. If one conservatively assumes 2
weeks post-treatment prophylaxis following antimalarial treatment and the highest risk of
reinfection of the included study sites, then the maximum risk of a new infection with P. vivax
within 63 days of P. falciparum would be 2.0%. The risks of P. vivax parasitaemia in our analy-
sis were thus at least 6- to 21-fold–greater than could be explained by reinfection alone.
It is possible that patients with mixed infections of P. falciparum with low-level P. vivax
parasitaemia were misdiagnosed as P. falciparum monoinfections. However, all of the ACTs
included in the analysis have high efficacy against P. vivax [63], and even if 10% of patients
had had submicroscopic P. vivax parasitaemia at presentation, the risk of recrudescent P. vivax
by day 63 would be no greater than 0.5%. Conversely, we may have underestimated the risk of
vivax recurrence because submicroscopic relapses were not quantified and the duration of fol-
low-up was restricted to 63 days, thus preventing detection of later relapses. In a longitudinal
cohort in which asymptomatic submicroscopic infections were quantified over a 12-month
period, there was a 2.4-fold–higher risk of asymptomatic vivax recurrence following asymp-
tomatic falciparum infections [64].
Our findings are more consistent with the P. vivax parasitaemia during follow-up arising
from activation of P. vivax hypnozoites present at the time of the initial presentation with P.
falciparum [5, 65, 66]. Importantly, the initial therapeutic response, as measured by parasite
clearance, was correlated with the subsequent risk of P. vivax. Patients taking longer to clear
their P. falciparum parasitaemia were at almost 2-fold–greater risk of P. vivax than those who
cleared their parasitaemia rapidly. Whilst this could reflect vulnerability of a host with low
immunity to both slower parasite clearance and recurrent parasitaemia, the increased risk of P.
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vivax was independent of the patients’ age, a surrogate marker of host immunity. We believe
this supports the hypothesis that vivax parasitaemia following falciparum malaria relates to a
host–parasite interaction that activates hypnozoites acquired from a prior infection. Haemoly-
sis has been postulated to trigger P. vivax reactivation [66, 67], although we found no correla-
tion between the early fall in Hb concentration and the risk of subsequent vivax parasitaemia.
Our study has a number of limitations. The systematic review included all P. falciparum
clinical trials between 1960 and 2018, although the analysis was restricted to patients who were
treated with an ACT with studies conducted between 1991 and 2018. The analysis included 42
studies, enrolling 15,341 patients in 12 malaria-endemic countries, and the quality of the
included studies suggested a low risk of systematic bias (S1 Text); however, there were signifi-
cant differences in these data and those included in our previous systematic review [7]. Four-
teen studies uploaded to the WWARN repository with P. vivax recurrences were not included
as part of the 153 studies in the previous review. Ten of these were not included in the initial
systematic review because the corresponding manuscripts reported neither the presence nor
absence of vivax recurrences. An additional limitation of our current analysis was the inability
to include data from 25 targeted studies. Although the patient demographics from these stud-
ies were similar to the included studies, they included a greater number of African studies,
which might have allowed better generalisability of results to this region. Furthermore, the
studies that were included were not equally representative of all vivax-endemic locations, with
the majority undertaken in southeast Asia and only a single study included from India. Studies
in the WWARN repository were only included into the analysis if they reported a P. vivax
recurrence in at least 1 treatment arm. This was justified because in many P. falciparum stud-
ies, P. vivax parasitaemia may not be deemed relevant to the efficacy analysis, and data may
not be recorded or shared with WWARN. Hence, it is possible that exclusion of these may
have systematically biased against studies without any P. vivax recurrence and thus overesti-
mated the risk of P. vivax. Reassuringly, only 3 out of 33 clinical trial arms in an independent
systematic review reported no P. vivax recurrences [60].
The rapid elimination of P. vivax will require a greater emphasis on addressing the hidden
reservoirs of the parasite, including individuals with asymptomatic carriage of blood- or liver-
stage parasites. Our analysis highlights that in coendemic areas, patients presenting with P. fal-
ciparum may be at significant risk of carrying dormant hypnozoites. Hence, whilst current
WHO guidelines only recommend treatment with a prolonged course of primaquine for
patients with P. vivax or a P. vivax–mixed-species infection [68], consideration should be
given to offering radical cure, with either primaquine or tafenoquine, with appropriate G6PD
testing, to patients presenting with P. falciparum monoinfection in coendemic regions. In view
of the heterogeneity in the risk of P. vivax and drug-induced haemolysis between locations,
such a strategy should be recommended with caution. The risk factors for P. vivax identified in
this analysis may help define populations for whom the benefit of a universal policy of radical
cure has greatest benefit but should be guided by complementary prospective clinical efficacy
studies, and in coendemic areas, these should include quantifying the subsequent risk of all
species of Plasmodia following antimalarial treatment.
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